Adding sodium-glucose cotransporter 2 (SGLT2) inhibitors to standard medical therapy for heart failure with preserved ejection fraction (HFpEF) provides just low-to-intermediate economic value to the ...

Sr. Director of Product at Aisera, Jigar brings 15+ years in enterprise AI, GenAI innovation, agentic automation and product-led growth. Enterprise AI is in the midst of a fundamental shift. The early ...

An exhaustive cost-benefit analysis of population genetic testing published in Annals of Internal Medicine concludes with a recommendation to U.S. health policymakers to adopt routine testing of ...

As an epidemiologist and physician, I’ve long been concerned about how health interventions for marginalized communities are evaluated. A new study explores that concern and offers some solutions for ...

Last month, the Institute for Clinical and Economic Review (ICER) issued a draft report on the cost-effectiveness of bluebird bio’s lovo-cel (lovotibeglogene autotemcel) and Vertex/CRISPR’s ...

CKD screening at age 55, combined with SGLT2 inhibitors, reduces kidney failure incidence and improves life expectancy across racial and ethnic groups. Non-Hispanic Black adults experience the most ...

This commentary argues that practitioners of cost-effectiveness analyses should incorporate dynamic drug pricing into formal cost-effectiveness analyses (CEAs). For reasons we discuss, doing so will ...

Receiving a notice from the Internal Revenue Service (IRS) about unpaid taxes can trigger feelings of fear, no matter what your original balance is. After all, the combination of the original tax ...

In education as in finance, a diverse portfolio can be the most sustainable investment. School District 11 in Colorado Springs hopes this kind of portfolio approach will enable it to continue to ...

Several new treatment combinations have been approved in metastatic renal cell carcinoma (mRCC). To determine the optimal therapy on the basis of cost and health outcomes, we performed a ...